Cosciens Biopharma Stock Today
| CSCI Stock | 2.90 0.05 1.75% |
Performance0 of 100
| Odds Of DistressLess than 46
|
COSCIENS Biopharma is trading at 2.90 as of the 17th of December 2024. This is a 1.75% up since the beginning of the trading day. The stock's open price was 2.85. COSCIENS Biopharma has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. COSCIENS Biopharma symbol was changed from AEZS on 9th of August 2024. The performance scores are derived for the period starting the 17th of November 2024 and ending today, the 17th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of May 2000 | Category Healthcare | Classification Health Care |
COSCIENS Biopharma is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 3.12 M outstanding shares of which 2.21 K shares are currently shorted by private and institutional investors with about 1.64 trading days to cover. More on COSCIENS Biopharma
Moving together with COSCIENS Stock
Moving against COSCIENS Stock
COSCIENS Stock Highlights
| Older Symbol | AEZS | ||||
| CEO President | ICDD MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
COSCIENS Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand COSCIENS Biopharma's financial leverage. It provides some insight into what part of COSCIENS Biopharma's total assets is financed by creditors.
| |||||
COSCIENS Biopharma (CSCI) is traded on NASDAQ Exchange in USA. It is located in 222 Bay Street, Toronto, ON, Canada, M5K 1E7 and employs 5 people. COSCIENS Biopharma was previously known as Aeterna Zentaris and was traded on NASDAQ Exchange under the symbol AEZS. COSCIENS Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.08 M. COSCIENS Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.12 M outstanding shares of which 2.21 K shares are currently shorted by private and institutional investors with about 1.64 trading days to cover.
COSCIENS Biopharma generates negative cash flow from operations
Check COSCIENS Biopharma Probability Of Bankruptcy
Ownership AllocationThe market capitalization of COSCIENS Biopharma is USD13.08 Million. Almost 91.99 percent of COSCIENS Biopharma outstanding shares are held by general public with 1.32 (percent) owned by insiders and only 6.69 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check COSCIENS Ownership Details
COSCIENS Biopharma Historical Income Statement
COSCIENS Stock Against Markets
COSCIENS Biopharma Corporate Executives
Elected by the shareholders, the COSCIENS Biopharma's board of directors comprises two types of representatives: COSCIENS Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of COSCIENS. The board's role is to monitor COSCIENS Biopharma's management team and ensure that shareholders' interests are well served. COSCIENS Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, COSCIENS Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Giuliano Fratta | Senior CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.